TScan Doses First Patient in Pivotal Phase 3 Trial, Q2 Loss Narrows
TCRX is trading near its 52-week low of $0.716 (8.5% above the low) on light trading volume (0.4× avg).
Summary
TScan reported Q2 results with a narrowed net loss of $30.36M, down from prior periods, driven by lower R&D and G&A spending. Revenue was minimal at $1.05M. More importantly, the company dosed its first patient in the pivotal Phase 3 ALLOHA-2 trial, a key step toward potential approval, with topline data expected mid-2028. Cash runway extends into Q2 2027, and the company plans to start Phase 1 studies for two additional candidates in Q4 2026. The Phase 3 initiation is the main event here — it moves the stock from a preclinical story to a registrational one, though the long timeline tempers immediate impact.
At the time of this announcement, TCRX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $0.72 to $2.57. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.